Monoclonal Antibody Therapeutics
•151 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (151)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Lilly relies on monoclonal antibody therapeutics across indications.
|
$1.05T |
$1075.63
-2.93%
|
|
JNJ
Johnson & Johnson
Johnson & Johnson's portfolio includes multiple monoclonal antibody therapeutics (e.g., DARZALEX, CARVYKTI, TECVAYLI, TALVEY) across oncology and immunology.
|
$499.71B |
$205.10
-1.15%
|
|
ABBV
AbbVie Inc.
AbbVie directly commercializes monoclonal antibody therapeutics (e.g., Skyrizi) as a core immunology asset.
|
$412.35B |
$223.62
-4.20%
|
|
AZN
AstraZeneca PLC
AZN develops monoclonal antibody therapeutics across oncology and immunology.
|
$295.00B |
$93.86
-1.37%
|
|
MRK
Merck & Co., Inc.
Keytruda and other antibody therapies place Merck in monoclonal antibody therapeutics.
|
$271.26B |
$109.76
+1.07%
|
|
AMGN
Amgen Inc.
Amgen's portfolio includes monoclonal antibody therapeutics such as Repatha and tezepelumab (TEZSPIRE).
|
$183.93B |
$329.26
-3.62%
|
|
GILD
Gilead Sciences, Inc.
Trodelvy’s antibody component and other cancer therapies align with Monoclonal Antibody Therapeutics.
|
$154.29B |
$120.16
-3.37%
|
|
PFE
Pfizer Inc.
Monoclonal antibody therapeutics represent a major therapeutic modality in Pfizer's portfolio and oncology pipeline.
|
$143.73B |
$25.20
-0.30%
|
|
BMY
Bristol-Myers Squibb Company
Opdivo is a monoclonal antibody immuno-oncology therapy, a core direct product in BMY's Growth Portfolio.
|
$115.45B |
$55.95
-1.36%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
Regeneron’s core business centers on monoclonal antibody therapeutics (e.g., Dupixent, Libtayo).
|
$86.09B |
$804.05
-1.01%
|
|
ZTS
Zoetis Inc.
Zoetis employs monoclonal antibodies for OA pain and dermatology therapies (e.g., Librela, Solensia, Cytopoint), defining a core Monoclonal Antibody Therapeutics product line.
|
$55.69B |
$126.80
+0.90%
|
|
ARGX
argenx SE
argenx's core offerings are monoclonal antibody therapeutics, including VYVGART.
|
$50.00B |
$793.25
-3.61%
|
|
TAK
Takeda Pharmaceutical Company Limited
Entrvyo/vedolizumab and other monoclonal antibody therapies place Takeda in Monoclonal Antibody Therapeutics.
|
$49.67B |
$16.33
+2.70%
|
|
ONC
BeOne Medicines Ltd.
TEVIMBRA is a monoclonal antibody therapy, placing the company in monoclonal antibody therapeutics.
|
$36.77B |
$318.87
-4.49%
|
|
BIIB
Biogen Inc.
Biogen's portfolio includes monoclonal antibody therapeutics (e.g., LEQEMBI) as a core modality.
|
$27.40B |
$183.66
-1.74%
|
|
BNTX
BioNTech SE
The company develops monoclonal antibody therapeutics (including bispecifics) for cancer, a core product area.
|
$24.06B |
$98.88
-1.20%
|
|
GMAB
Genmab A/S
Genmab develops and commercializes monoclonal antibody therapeutics (e.g., antibody-based oncology medicines).
|
$21.75B |
$33.52
-1.14%
|
|
INCY
Incyte Corporation
Monoclonal Antibody Therapeutics is a direct product modality for Monjuvi (tafasitamab) and similar antibody-based cancer therapies.
|
$21.59B |
$105.39
-4.68%
|
|
ROIV
Roivant Sciences Ltd.
Immunovant's FcRn-targeting therapies (e.g., IMVT-1402, batoclimab) are monoclonal antibody therapeutics.
|
$15.01B |
$21.64
-1.52%
|
|
SMMT
Summit Therapeutics Inc.
Ivonescimab is an antibody-based therapeutic, aligning with Monoclonal Antibody Therapeutics as a core modality.
|
$14.12B |
$18.61
-2.13%
|
|
RDY
Dr. Reddy's Laboratories Limited
Monoclonal antibody therapeutics emphasis via biosimilar strategies (e.g., abatacept, rituximab, pembrolizumab collaboration).
|
$11.39B |
$13.41
-1.97%
|
|
ELAN
Elanco Animal Health Incorporated
Monoclonal Antibody Therapeutics platform (CPMA and IL‑31 related programs) constitutes a key technology and product approach.
|
$11.35B |
$23.16
+1.38%
|
|
JAZZ
Jazz Pharmaceuticals plc
Zanidatamab is a monoclonal antibody therapeutic, aligning with Monoclonal Antibody Therapeutics.
|
$10.27B |
$160.76
-5.08%
|
|
RNA
Avidity Biosciences, Inc.
Monoclonal Antibody Therapeutics: uses antibody component for targeting in the AOC platform.
|
$9.31B |
$72.31
-0.08%
|
|
MRUS
Merus N.V.
Core product category: monoclonal antibody therapeutics used in cancer indications.
|
$6.81B |
$90.00
|
|
TGTX
TG Therapeutics, Inc.
BRIUMVI is TG Therapeutics' flagship monoclonal antibody therapeutic (anti-CD20) for relapsing MS, the core product driving revenue and growth.
|
$4.81B |
$30.30
-0.13%
|
|
APGE
Apogee Therapeutics, Inc.
Directly develops and manufactures monoclonal antibody therapeutics (APG777, APG808, APG990).
|
$4.71B |
$75.44
-4.45%
|
|
IMVT
Immunovant, Inc.
IMVT-1402 and batoclimab are monoclonal antibodies targeting FcRn, aligning with monoclonal antibody therapeutics.
|
$4.66B |
$26.11
-2.30%
|
|
SRRK
Scholar Rock Holding Corporation
Directly develops and markets monoclonal antibody therapeutics (apitegromab, SRK-439, SRK-181) across SMA, obesity/metabolic, and oncology.
|
$4.25B |
$41.41
-6.38%
|
|
KNSA
Kiniksa Pharmaceuticals, Ltd.
KPL-387 is a monoclonal antibody targeting IL-1R1, placing the pipeline in monoclonal antibody therapeutics.
|
$3.14B |
$41.57
-2.00%
|
|
VERA
Vera Therapeutics, Inc.
Atacicept is a biologic therapeutic (dual BAFF/APRIL inhibitor) with a monoclonal antibody–like profile, placing Vera's lead program under Monoclonal Antibody Therapeutics.
|
$3.11B |
$47.41
-2.61%
|
|
CNTA
Centessa Pharmaceuticals plc
LockBody is an antibody-based platform; its advances map to 'Monoclonal Antibody Therapeutics'.
|
$3.04B |
$22.07
-2.73%
|
|
BEAM
Beam Therapeutics Inc.
BEAM-103 involves an anti-CD117 monoclonal antibody; includes Monoclonal Antibody Therapeutics as part of its conditioning strategy.
|
$2.93B |
$28.00
-3.23%
|
|
ADPT
Adaptive Biotechnologies Corporation
Monoclonal Antibody Therapeutics tag aligns with autoreactive TCR targeting and antibody programs.
|
$2.55B |
$15.63
-6.55%
|
|
VRDN
Viridian Therapeutics, Inc.
Lead programs Veligrotug and VRDN-003 are monoclonal antibodies targeting IGF-1R, i.e., Monoclonal Antibody Therapeutics.
|
$2.50B |
$30.19
-1.24%
|
|
RCUS
Arcus Biosciences, Inc.
Domvanalimab is a monoclonal antibody therapeutic, placing Arcus in the Monoclonal Antibody Therapeutics category.
|
$2.47B |
$20.96
-9.66%
|
|
RARE
Ultragenyx Pharmaceutical Inc.
UX143 is a monoclonal antibody; Ultragenyx' portfolio includes monoclonal antibody therapeutics (Crysvita, Evkeeza, UX143).
|
$2.33B |
$23.04
-4.79%
|
|
OGN
Organon & Co.
Monoclonal antibody therapeutics including Emgality marketed within Organon's portfolio.
|
$2.13B |
$8.23
+0.55%
|
|
ZLAB
Zai Lab Limited
Significant monoclonal antibody therapeutics activity across oncology/immunology assets.
|
$2.09B |
$18.50
-2.81%
|
|
SNDX
Syndax Pharmaceuticals, Inc.
Niktimvo axatilimab-csfr is a monoclonal antibody therapy, fitting Monoclonal Antibody Therapeutics.
|
$1.90B |
$21.24
-3.93%
|
|
SYRE
Spyre Therapeutics, Inc.
Spyre's pipeline comprises engineered monoclonal antibodies (SPY001/SPY002/SPY003) targeting α4β7, TL1A, and IL-23 for IBD and RA.
|
$1.88B |
$29.86
-3.82%
|
|
ZYME
Zymeworks Inc.
Company develops monoclonal antibody therapeutics as a core modality.
|
$1.87B |
$23.08
-7.12%
|
|
ALMS
Alumis Inc. Common Stock
Lonigutamab is a monoclonal antibody therapy, a direct product in the biopharma pipeline.
|
$1.86B |
$18.05
+0.73%
|
|
CLDX
Celldex Therapeutics, Inc.
Barzolvolimab is a therapeutic monoclonal antibody, placing Celldex in Monoclonal Antibody Therapeutics.
|
$1.84B |
$27.02
-2.67%
|
|
IMNM
Immunome, Inc.
Antibody-based therapeutics component of ADCs justifies Monoclonal Antibody Therapeutics tagging.
|
$1.74B |
$20.62
+3.20%
|
|
UPB
Upstream Bio, Inc.
Verekitug is a monoclonal antibody therapeutic targeting the TSLP receptor, directly aligning with Monoclonal Antibody Therapeutics.
|
$1.51B |
$27.55
-1.89%
|
|
KOD
Kodiak Sciences Inc.
Lead assets are monoclonal antibody therapeutics designed for retinal disease, aligning with Monoclonal Antibody Therapeutics.
|
$1.43B |
$26.71
-1.31%
|
|
NRIX
Nurix Therapeutics, Inc.
The narrative references antibody therapies in addition to small molecule degraders, aligning with Monoclonal Antibody Therapeutics.
|
$1.41B |
$18.66
+0.89%
|
|
ANAB
AnaptysBio, Inc.
Lead programs are monoclonal antibody therapeutics (antibodies such as rosnilimab, ANB033, ANB101).
|
$1.27B |
$43.91
-2.89%
|
|
BHVN
Biohaven Ltd.
BHVN's Trop2 ADC program aligns with Monoclonal Antibody Therapeutics as a core oncology modality.
|
$1.24B |
$11.32
-3.53%
|
|
ABCL
AbCellera Biologics Inc.
Company is developing monoclonal antibody therapeutics through wholly-owned programs ABCL635 and ABCL575.
|
$1.23B |
$4.08
-1.33%
|
|
TRML
Tourmaline Bio, Inc.
Pacibekitug is a monoclonal antibody therapeutic targeting IL-6, fitting Monoclonal Antibody Therapeutics.
|
$1.23B |
$47.98
+0.01%
|
|
DNTH
Dianthus Therapeutics, Inc.
Lead product is a monoclonal antibody therapeutic targeting active C1s, a core product category.
|
$1.23B |
$37.85
-0.62%
|
|
OCS
Oculis Holding AG
OCS-02 Licaminlimab is an antibody-based therapeutic (monoclonal antibody therapeutics).
|
$1.17B |
$21.81
+4.01%
|
|
INBX
Inhibrx Biosciences, Inc.
Monoclonal antibody therapeutics addressing cancer targets with multivalent formats.
|
$1.10B |
$76.28
+0.47%
|
|
OPK
OPKO Health, Inc.
ModeX antibody therapies fall under monoclonal antibody therapeutics.
|
$1.08B |
$1.35
-0.37%
|
|
XNCR
Xencor, Inc.
Core output includes engineered monoclonal antibody therapeutics via the XmAb platform.
|
$1.07B |
$14.01
-6.29%
|
|
ERAS
Erasca, Inc.
ERAS-12 is an EGFR biparatopic antibody, constituting Monoclonal Antibody Therapeutics.
|
$1.02B |
$3.58
+6.07%
|
|
OMER
Omeros Corporation
Narsoplimab and zaltenibart OMS906 are monoclonal antibody therapeutics, a core product class for Omeros.
|
$958.91M |
$13.94
-1.10%
|
|
BCAX
Bicara Therapeutics Inc. Common Stock
Lead product is a monoclonal antibody–type therapeutic, aligning with Monoclonal Antibody Therapeutics.
|
$936.84M |
$16.34
-4.83%
|
|
VIR
Vir Biotechnology, Inc.
VIR's antibody-based approaches include monoclonal antibody therapeutics targeting cancer antigens.
|
$855.73M |
$5.92
-3.98%
|
|
JANX
Janux Therapeutics, Inc.
Therapies revolve around monoclonal antibody-based modalities (including bispecific antibodies).
|
$840.11M |
$13.75
-1.65%
|
|
NKTR
Nektar Therapeutics
NKTR-0165 is a monoclonal antibody therapeutic (TNFR2 agonist), aligning with Monoclonal Antibody Therapeutics.
|
$827.50M |
$41.90
-3.70%
|
|
AVBP
ArriVent BioPharma, Inc. Common Stock
ADC programs involve monoclonal antibody components; ARR-217 implies monoclonal antibody therapeutics as part of the ADC strategy.
|
$796.77M |
$19.45
-0.99%
|
|
ATXS
Astria Therapeutics, Inc.
Astria Therapeutics develops monoclonal antibody therapeutics (navenibart and STAR-0310).
|
$744.94M |
$12.96
-1.86%
|
|
EBS
Emergent BioSolutions Inc.
Ebanga is a monoclonal antibody therapeutic developed by Emergent for Ebola; this aligns with the Monoclonal Antibody Therapeutics investable theme.
|
$741.58M |
$13.21
-5.00%
|
|
CTMX
CytomX Therapeutics, Inc.
PROBODY therapeutics are monoclonal antibody–based biologics, aligning with Monoclonal Antibody Therapeutics.
|
$709.13M |
$4.21
-1.98%
|
|
ZBIO
Zenas BioPharma, Inc.
Obexelimab is a monoclonal antibody therapeutic developed by the company.
|
$695.24M |
$16.56
+0.30%
|
|
CGEM
Cullinan Therapeutics, Inc.
Antibody-based therapeutics (monoclonal antibodies) are a direct product modality for CLN-978 and velinotamig.
|
$646.27M |
$11.15
+1.92%
|
|
ABSI
Absci Corporation
Internal programs ABS-101/ABS-201/ABS-301/ABS-501 are antibody-based therapeutics targeting oncology and immunology, aligning with Monoclonal Antibody Therapeutics.
|
$559.21M |
$3.87
+3.34%
|
|
RAPT
RAPT Therapeutics, Inc.
RPT904 is a monoclonal antibody therapeutic, fitting Monoclonal Antibody Therapeutics.
|
$536.16M |
$31.67
-2.31%
|
|
ANNX
Annexon, Inc.
Annexon's lead programs are monoclonal antibody therapeutics (ANX005, ANX009) targeting C1q.
|
$515.37M |
$4.67
-6.87%
|
|
VNDA
Vanda Pharmaceuticals Inc.
Imsidolimab is a monoclonal antibody therapeutic targeting IL-36R for generalized pustular psoriasis.
|
$504.62M |
$7.41
-13.23%
|
|
PRTA
Prothena Corporation plc
Prothena's core assets are monoclonal antibody therapeutics (PRX012, PRX019, PRX123, etc.) across neurodegenerative diseases, including Alzheimer's and other indications.
|
$491.47M |
$8.96
-1.86%
|
|
SIGA
SIGA Technologies, Inc.
SIGA's pipeline includes fully human monoclonal antibodies licensed from Vanderbilt, aligning with Monoclonal Antibody Therapeutics.
|
$490.50M |
$6.77
-1.17%
|
|
IMMP
Immutep Limited
IMP761 is described as a LAG-3 agonist antibody, aligning with Monoclonal Antibody Therapeutics.
|
$442.50M |
$3.00
-1.32%
|
|
PRTC
PureTech Health plc
LYT-200 is a monoclonal antibody therapeutic, a core biologics modality.
|
$416.59M |
$17.15
+2.13%
|
|
ADCT
ADC Therapeutics S.A.
ZYNLONTA uses a monoclonal antibody as its targeting moiety, fitting Monoclonal Antibody Therapeutics.
|
$410.62M |
$3.54
-3.01%
|
|
YMAB
Y-mAbs Therapeutics, Inc.
DANYELZA (naxitamab-gqgk) is a monoclonal antibody therapeutic.
|
$389.89M |
$8.61
|
|
ITOS
iTeos Therapeutics, Inc.
Belrestotug is a monoclonal antibody targeting TIGIT, indicating direct production of monoclonal antibody therapeutics.
|
$388.48M |
$10.15
|
|
MNPR
Monopar Therapeutics Inc.
MNPR-101 is a humanized monoclonal antibody targeting uPAR, fitting Monoclonal Antibody Therapeutics.
|
$380.87M |
$56.59
-8.33%
|
|
VIGL
Vigil Neuroscience, Inc.
Direct product: Vigil's lead program iluzanebart is a fully human monoclonal antibody TREM2 agonist, categorizing under Monoclonal Antibody Therapeutics.
|
$375.71M |
$8.05
|
|
ACIU
AC Immune S.A.
Monoclonal Antibody Therapeutics – AC Immune develops conformation-specific monoclonal antibodies via SupraAntigen platforms.
|
$370.32M |
$3.42
-7.20%
|
|
FBRX
Forte Biosciences, Inc.
FB102 is a monoclonal antibody therapeutic targeting CD122, directly matching Monoclonal Antibody Therapeutics.
|
$326.98M |
$25.60
-2.66%
|
|
ACRS
Aclaris Therapeutics, Inc.
Bosakitug and other assets are monoclonal antibody therapeutics, matching Monoclonal Antibody Therapeutics.
|
$290.33M |
$2.63
-1.68%
|
|
IVVD
Invivyd, Inc.
Invivyd's PEMGARDA and pipeline candidate VYD2311 are monoclonal antibody therapeutics targeting evolving viral threats, making Monoclonal Antibody Therapeutics the core product category.
|
$285.94M |
$2.29
-3.99%
|
|
ZURA
Zura Bio Limited
Crebankitug and torudokimab are monoclonal antibodies in Zura Bio's pipeline (Monoclonal Antibody Therapeutics).
|
$261.37M |
$4.01
-0.25%
|
|
STTK
Shattuck Labs, Inc.
SL-325 is a monoclonal antibody targeting DR3, making Monoclonal Antibody Therapeutics a direct product category.
|
$229.94M |
$4.55
-5.21%
|
|
SLRN
Acelyrin, Inc.
Lonigutamab is a monoclonal antibody therapeutic (IGF-1R) being developed as a treatment for TED, aligning with Monoclonal Antibody Therapeutics.
|
$228.61M |
$2.27
|
|
VYGR
Voyager Therapeutics, Inc.
VY7523 is a monoclonal antibody targeting tau, category: Monoclonal Antibody Therapeutics.
|
$226.87M |
$4.05
-0.86%
|
|
AVTX
Avalo Therapeutics, Inc.
AVTX-9.00 is an anti-IL-1β monoclonal antibody, directly fitting Monoclonal Antibody Therapeutics.
|
$222.80M |
$17.11
+0.97%
|
|
RZLT
Rezolute, Inc.
Ersodetug is a human monoclonal antibody designed to treat HI by modulating insulin signaling, representing a monoclonal antibody therapeutic product.
|
$213.41M |
$2.40
+2.34%
|
|
TLSA
Tiziana Life Sciences Ltd
TLSA's lead product Foralumab is a fully human monoclonal antibody therapeutic, placing the company in Monoclonal Antibody Therapeutics.
|
$180.31M |
$1.48
-1.67%
|
|
ALEC
Alector, Inc.
Latozinemab and AL101 are monoclonal antibody therapeutics in the pipeline.
|
$178.13M |
$1.75
-0.28%
|
|
CYDY
CytoDyn Inc.
Leronlimab is a monoclonal antibody therapeutic, aligning CytoDyn with Monoclonal Antibody Therapeutics.
|
$176.24M |
$0.27
|
|
SRZN
Surrozen, Inc.
Company develops monoclonal antibody therapeutics targeting tissue-specific Wnt signaling.
|
$171.15M |
$19.62
-1.75%
|
|
CHRS
Coherus Oncology, Inc.
LOQTORZI is a differentiated PD-1 monoclonal antibody and commercial oncology product, aligning with Monoclonal Antibody Therapeutics.
|
$166.21M |
$1.50
+5.24%
|
|
CGEN
Compugen Ltd.
COM701 and GS-0321 are monoclonal antibody therapeutics in development, aligning with Monoclonal Antibody Therapeutics.
|
$160.88M |
$1.62
-5.52%
|
|
THTX
Theratechnologies Inc.
Trogarzo is a monoclonal antibody therapy for multidrug-resistant HIV, a direct product offering.
|
$155.87M |
$3.39
|
|
CBIO
Crescent Biopharma, Inc.
The therapies are monoclonal antibody–based biologics, including antibody modalities.
|
$151.98M |
$11.00
+0.55%
|
Showing page 1 of 2 (151 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
